舒肝补肾健脾利湿方案联合恩替卡韦治疗慢性肝炎的临床疗效

Clinical efficacy of scheme of shugan bushen jianpi lishi combined with entecavir in the treatment of chronic hepatitis

目的探讨舒肝补肾健脾利湿方案联合恩替卡韦治疗慢性肝炎的临床疗效。方法选取秭归县中医院2018年1月—2020年5月收治的慢性肝炎患者100例,随机分为对照组与观察组,各50例。对照组予以恩替卡韦胶囊治疗,观察组在对照组基础上予以舒肝补肾健脾利湿方案治疗。比较2组临床疗效,治疗前后丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBiL)、白蛋白(ALB),病毒学指标〔包括乙肝e抗原(HBeAg)转阴率、乙型肝炎病毒(HBV)-DNA转阴率〕,并观察2组不良反应发生情况。结果观察组治疗总有效率高于对照组(P<0.05)。治疗前2组ALT、AST、TBiL、ALB比较,差异无统计学意义(P>0.05);治疗后观察组ALT、AST、TBiL低于对照组,ALB高于对照组(P<0.05)。观察组HBeAg转阴率、HBV-DNA转阴率高于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论舒肝补肾健脾利湿方案联合恩替卡韦治疗慢性肝炎的临床疗效确切,可有效提高HBeAg转阴率、HBV-DNA转阴率,改善患者肝功能,且安全性较高。

Objective To explore clinical efficacy of scheme of shugan bushen jianpi lishi combined with entecavir in the treatment of chronic hepatitis.Methods A total of 100 cases of patients with chronic hepatitis were selected from January 2018 to May 2020 in Zigui County Traditional Chinese Medicine Hospital,which were randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with entecavir capsule,while the observation group was treated with scheme of shugan bushen jianpi lishi on the basis of the control group.Clinical efficacy,ALT,AST,TBiL,ALB before and after treatment,virological indexes(including HBeAg negative rate and HBV-DNA negative rate)were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of observation group was higher than control group(P<0.05).Before treatment,there was no significant difference in ALT,AST,TBiL and ALB between the two groups(P>0.05);after treatment,the observation group of ALT,AST and TBiL were lower than control group,while ALB was higher than control group(P<0.05).The negative rates of HBeAg and HBV-DNA in observation group were higher than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Scheme of shugan bushen jianpi lishi combined with entecavir have an exact clinical effect for chronic hepatitis,which can effectively improve the negative rate of HBeAg and HBVDNA,improve the liver function of patients,and with high safety.